General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
Consolidated revenue for the three months to June 2026 was ₹178.67 crore, against ₹33.39 crore a year earlier. That is a jump of 435%. Management says the year-on-year comparison is not like-for-like, because the earlier quarter contained no Australian company. Noumed was consolidated from 12 November 2025. Two quarters of the enlarged base now exist, and this is the second.
Operating profit was ₹23.52 crore and profit after tax ₹7.92 crore. Earnings per share were ₹1.79. Revenue slipped from ₹197.93 crore in the previous quarter, and profit after tax from ₹13.16 crore. Management attributes that fall to lower revenue and a normalised tax charge. The three months to March 2026 had carried a tax line of negative ₹0.76 crore.
The board meeting of 11 August ran to eighteen items. Among them: ₹101.85 crore of listing proceeds proposed for two assets the prospectus did not name, a re-appointment, a resignation and an ESOP ratification. ESOP means employee stock options, shares offered to staff as part of their pay. The board also cleared the incorporation of an American subsidiary, which management described as “too premature” to have a strategy.
The year to March 2026 closed with revenue of ₹381 crore and profit after tax of ₹14.26 crore. Cash and bank balances stood at ₹416.97 crore, against ₹2.09 crore a year earlier. The primary raise of ₹285 crore was completed in March 2026.
2. Introduction
Sai Parenteral’s Ltd was incorporated in 2001. Parenteral medicines are given by injection or drip rather than swallowed. The company says it has evolved from a parenteral-focused player into a diversified formulations platform. That shift has reduced its dependency on injectables, on the company’s own account. A firm named after injectables has spent two decades making itself less about injectables.
The listed history is short. The initial public offering completed in March 2026, with a primary raise of ₹285 crore. The shares listed on 2 April 2026. The company was not required to publish quarterly results for the three months to June 2025. That comparative figure exists only because someone put it in the statement.
The acquisition record set out by the company runs to four deals. Unit III at Bhongir came in the year to March 2022 for ₹24 crore. Unit IV at Bollaram followed a year later for ₹11 crore. Revat Laboratories came the year after that for ₹28 crore. Noumed Pharmaceuticals came in the year to March 2026. The company bought 74.64% of it for AUD 22 million, which it puts at ₹129 crore. Two more deals are proposed for the year to March 2027. One is 60% of Saicriti Pharma for ₹83.83 crore. The other is 60% of Prathyak Laboratories for ₹15 crore.
The group now has five subsidiaries, two of them step-down. A step-down subsidiary is owned by another subsidiary rather than directly. They sit across India, Singapore, Australia and New Zealand, and a sixth entity is under incorporation in the United States. The corporate structure describes the Singapore entity as a holding company for cross-border transactions.
The Australian over-the-counter supply agreement, worth AUD 202 million, took effect on 1 July 2026. Over the counter means sold in a pharmacy without a prescription. The three months to June 2026 end one day before that contract starts. Management says it begins contributing in the quarter to September 2026.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
Three engines, on the company’s own description: contract manufacturing for export, branded generics, and the Noumed platform.
The first is a CDMO business, meaning a firm that develops and makes medicines for other companies under contract. The work runs end to end: development, validation, stability testing, dossiers, international filings and commercial supply. The company states that no CDMO work is undertaken domestically, so the entire contract book serves export markets. It made up 63% of net revenue in the year to March 2026. Three years earlier it was 5%, which the company puts at a compound rate of 355.6% a year. The cycle is slow by construction. Developing a product takes roughly 12 to 14 months. Securing approval takes another 12 to 14 months. Supply then typically continues for the life of the registration. Two years of paperwork, then an annuity.
Branded generics were 37% of net revenue in the year to March 2026. Generics are copies of medicines whose patents have expired. The unit sells them under the company’s own brands, to government agencies, hospitals, super stockists and Jan Aushadhi outlets. It also exports through 7 distributors across 10 countries. Institutional share of that vertical fell from 61% to 19% over the three years to March 2026. Private-sector share rose to 81%.
Then Noumed, which is the genuinely unusual part. Australian retail pharmacy chains own the consumer brands but hold no registrations and do no manufacturing. Noumed holds the
